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ABSTRACT
Myxoid sarcoma (MLS) is one of the most common types of malignant soft tissue 
tumors. MLS is characterized by the FUS-DDIT3 or EWSR1-DDIT3 fusion oncogenes 
that encode abnormal transcription factors. The receptor tyrosine kinase (RTK) 
encoding RET was previously identified as a putative downstream target gene to 
FUS-DDIT3 and here we show that cultured MLS cells expressed phosphorylated 
RET together with its ligand Persephin. Treatment with RET specific kinase inhibitor 
Vandetanib failed to reduce RET phosphorylation and inhibit cell growth, suggesting 
that other RTKs may phosphorylate RET. A screening pointed out EGFR and ERBB3 
as the strongest expressed phosphorylated RTKs in MLS cells. We show that ERBB3 
formed nuclear and cytoplasmic complexes with RET and both RTKs were previously 
reported to form complexes with EGFR. The formation of RTK hetero complexes could 
explain the observed Vandetanib resistence in MLS. EGFR and ERBB3 are clients of 
HSP90 that help complex formation and RTK activation. Treatment of cultured MLS 
cells with HSP90 inhibitor 17-DMAG, caused loss of RET and ERBB3 phosphorylation 
and lead to rapid cell death. Treatment of MLS xenograft carrying Nude mice resulted 
in massive necrosis, rupture of capillaries and hemorrhages in tumor tissues. We 
conclude that complex formation between RET and other RTKs may cause RTK 
inhibitor resistance. HSP90 inhibitors can overcome this resistance and are thus 
promising drugs for treatment of MLS/RCLS.
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INTRODUCTION
Myxoid liposarcoma (MLS) accounts for more 
than a third of all liposarcoma cases [1]. This entity 
is characterized by t(12;16) or more rarely t(12;22) 
chromosome translocations that result in fusions of the 
transcription factor gene DDIT3 (also known as CHOP 
or GADD153) to FUS (also designated TLS) or to EWSR1 
[2–4]. The chimerical FUS-DDIT3 and EWSR1-DDIT3 
encoded proteins are believed to function as abnormal 
transcription factors and FUS-DDIT3 was reported to 
cause MLS like tumors in experimental mouse models 
[3, 5]. Most MLS tumors carry normal and functional 
TP53 genes and are genetically stable [6, 7].
A subtraction screen for target genes downstream 
of FUS-DDIT3 identified the proto oncogene RET among 
genes that are expressed in FUS-DDIT3 carrying MLS, 
but not in normal adipose tissue or in benign lipoma [8]. 
RET encodes a receptor tyrosine kinase (RTK) [9–11] that 
may bind four alternative RET ligands. Ligand binding 
promotes RET complex formation, auto-phosphorylation 
[12] and activation of downstream signaling pathways 
[13–16]. RET can also form active heterodimers with the 
epithelial growth factor receptor (EGFR) [17] and recently 
the receptor tyrosine kinase MET was also reported to 
form heterodimers with RET in MLS tissues [18]. Such 
hetero-complex formation and activation of RET may 
operate in MLS cells as EGFR is strongly expressed in the 
tumor cells [19]. The observed co-expression of RET and 
EGFR in MLS prompted further investigation of RTKs as 
possible drug targets and their role in tumor development.
In the present study, we analyzed the expression of 
RET and its ligands in 8 MLS cases and 4 MLS derived 
cell lines and investigated its potential interaction with 
other RTK species. RTK inhibitors were tested for growth/
survival effects in MLS cell lines. The HSP90 chaperone 
proteins enlist RET and several other RTKs as client 
proteins [20, 21]. HSP90 inhibitors were thus tested for 
effects in MLS cell lines and in an MLS xenograft model.
RESULTS
RET mRNA and protein is expressed in MLS cell 
lines and tumor tissues
A meta-analysis of public expression array datasets 
from 434 human tumor samples, pointed out expression 
of RET as typically for MLS compared to other soft tissue 
tumors (Supplementary Data Table 1).
RT-PCR analysis with three primer pairs that 
amplified sequences encoding extracellular, transmem­
brane and tyrosine kinase encoding parts showed that full 
length RET transcripts were expressed in all MLS tumors 
investigated (Figure 1A). Western blot analysis of RET in 
protein extracts from three MLS cell lines showed reactive 
bands at 170 kDa, the reported size for the longest RET 
isoform (Figure 1B), and immunohistochemical (IHC) 
analysis of tumor tissues detected RET protein in both 
nuclei and cytoplasm of most tumor cells (Figure 1C). 
The RET protein is phosphorylated in MLS cells
Ligands or activating mutations cause autophos-
phorylation of RET Y905 [22]. At least a fraction of the 
RET molecules reacted with a phospho­Y905 specific 
antibody in MLS (Figure 1B). Sequencing of four MLS 
cell lines showed that the Y905 phosphorylation was not 
caused by activating mutations in RET [6]. Other full 
exome sequencing efforts on large cohorts of MLS also 
report normal RET gene sequences [7].
MLS tumors express the RET ligand Persephin 
but not co-receptors GFRα1–4
Activation of RET could be caused by RET ligands 
in MLS. Our analysis of MLS cell lines showed that 
they contained mRNAs for glia derived neurotrophic 
factor (GDNF), neurturin (NRTN) and persephin (PSPN) 
but RNA extracted from tumor tissues contained only 
the PSPN transcript (Figure 1A). Sequence analysis 
of PSPN cDNA from MLS cell lines showed a normal 
PSPN sequence (data not shown) and Western blot 
analysis of protein extracts from MLS cells showed 
two bands at the sizes reported for the unprocessed 
PSPN precursor (17 kDa) and the mature PSPN 
(12 kDa) (Figure 1B). Both bands were detected with 
antibodies against N-terminal and C-terminal parts of 
PSPN. IHC analysis with PSPN specific antibodies in 
sections from eight MLS tumors showed a cytoplasmic 
staining of the tumor cells in all cases (Figure 1C). 
RT-PCR analysis of RET co-receptors GFRα1–4 in 
four MLS tumors and three MLS-cell lines detected no 
transcripts (data not shown).
RET RTK inhibitor Vandetanib fails to block 
RET Y905 phosphorylation and cell growth/
survival of MLS derived cells lines
The RTK inhibitor Vandetanib is reported to inhibit 
RET kinase activity with 50% inhibition at 100 nM 
[23]. However, treatment of MLS cells with up to 2 µM 
Vandetanib failed to reduce RET Y905 phosphory-
lation and cell proliferation/survival (Supplementary 
Figure 1A and 1B). The observed phosphorylation of RET 
Y905 may therefore depend on other, Vandetanib-resistant 
kinases.
Phosphorylated EGFR and ERBB3 are 
expressed in MLS cells and tissues
A dot blot screen for phosphorylated RTKs pointed 
out EGFR and ERBB3 as the most strongly expressed, 
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phosphorylated RTKs in MLS cell lines (Figure 2A). 
Western blot analysis confirmed that EGFR (130 kDa) and 
ERBB3 (190 kDa) proteins were expressed in three MLS 
cell lines and that at least a fraction of these proteins were 
phosphorylated at their activation specific positions Y1068 
and Y1289, respectively (Figure 2B). IHC studies of MLS 
tissues showed surface/cytoplasmic expression of EGFR 
whereas ERBB3 showed nuclear/cytoplasmic localization 
in MLS tissues and cell lines (Figure 2C).
RET and ERBB3 proteins form  
complex in MLS cells
RET and EGFR as well as EGFR and ERBB3 
are known to form hetero-complexes [17, 24]. Our IHC 
observation that ERBB3 and RET partially co-localizes 
(Figures 1C and 2C), raised our suspicion that RET and 
ERBB3 also could form complexes. Proximity ligation assays 
(PLA) showed that ERBB3 and RET localized close 
enough for PLA detection (Figure 2D), indicating that 
these molecules indeed form hetero-complex in MLS 
cells. The hetero­complex formation was confirmed by co­
immunoprecipitation one word of RET with EGFP-antibodies 
in ERBB3-EGFP transfected MLS cells (Figure 2F).
Our IHC and PLA results showed a mixed 
cytoplasmic and nuclear expression of RET and ERBB3 
(Figures 1C, 2C and Supplementary Film Clips).
The EGFR tyrosine kinase inhibitor Gefitinib 
fails to inhibit cell growth/survival of MLS 
derived cells lines
EGFR specific Gefitinib failed to inhibit cell 
growth and survival of MLS cell lines at concentrations 
with maintained RTK specificity [25] (Supplementary 
Figure 1C). Combinations of Gefitinib and Vandetanib also 
Figure 1: Expression of RET and ligands in MLS cell lines and tissues. (A) RT-PCR analysis of the tyrosine kinase encoding 
parts of the RET transcript and of ligands PSPN, GDNF and NRTN. Lanes 402–91, 2645–94, 1765–92 and 1955–91 are MLS derived cell 
lines, 293 is a short term cultured thyroid cancer, MLS 1–8 are material from MLS tumor tissues. Thyroid Ca is thyroid carcinoma tumor 
tissue sample used as positive control. Fibroblasts were used as negative control as they were previously found to be negative for RET 
expression [11]. (B) Western blot analysis of MLS cell lines 402–91, 2654–94, 1765–91 and 1955–91 and negative control fibroblasts. 
Antibodies against RET, RET phospho-Y905 and RET ligand PSPN C-terminal. (C) Immunohistochemistry of sections from one MLS 
case, representative of 8 tested. Sections stained with antibodies specific for the RET and PSPN proteins. Exclusion of the primary antibody 
abolished all staining of the sections. Size bars are 20 μm.
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Figure 2: Expression of EGFR and ERBB3 in MLS cell lines and tissues. (A) RTK phospho-array analysis of MLS 402–91 
and 1765–92 cell lines. Cultured normal fibroblasts as control sample. (B) Western blot analysis of EGFR, EGFR phospho-Y1068, ERBB3 
and ERBB3 phospho-Y1289 in MLS cell lines 402–91, 2645–94, 1765–92. (C) Immunohistochemistry of sections from one MLS case 
representative of 8. Sections stained with antibodies specific for the EGFR and ERBB3 proteins. Exclusion of the primary antibody 
abolished all staining of the sections. Size bars are 20 μm. (D) PLA analysis of RET­ERBB3 interaction. AB: indicates specificity of 
antibodies used. Red dots indicate signals from antibodies that are located close enough for the ligation assay to score. The RET and ERBB3 
panels shows signals from antibodies targeting RET and ERBB3, respectively, and the RET-ERBB3 panel shows signals from interactions 
between one RET and one ERBB3 antibody as described in materials and methods. (E) Quantification of PLA signals from RET­RET, 
ERBB3-ERBB3 and RET-ERBB3 antibody combinations in cytoplasm and nuclei. Mean numbers of signals and standard error of means 
shown from five randomly selected cells of each experiment. (F) Co-immunoprecipitation of RET protein with EGFP antibodies in ERBB3-
EGFP and EGFP transfected MLS cell line 1765–92. Western blot detection of precipitated proteins is shown. IN: Input proteins for IP, NB: 
non-bound proteins, B: precipitated proteins.
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failed to block growth/survival at concentrations within 
their range of specificity (Supplementary Figure 1D).
The HSP90 inhibitor 17-DMAG causes loss 
of phosphorylated RET, EGFR and ERBB3 
proteins in MLS cell lines
The failure to inhibit RET Y905 phosphorylation 
with specific tyrosine kinase inhibitors could possibly 
be explained by formation of multi-member protein 
complexes between RET, EGFR, ERBB3 and perhaps 
yet other tyrosine kinases. This hypothesis led us to 
investigate other means of modifying the activity of the 
RTKs. RET, EGFR and ERBB3 are listed among clients 
of HSP90 chaperone proteins [20, 21]. Cell proliferation 
and survival assays showed an LD50 between 10 and 
30 nM for the HSP90 inhibitor 17-DMAG in the tested 
MLS cell lines (Figure 3A). The RET Y905, and ERBB3 
Y1289 phosphorylation levels were reduced 24 hours after 
addition of 17-DMAG while the total RET and ERBB3 
protein levels were unaffected (Figure 3B).
The HSP90 inhibitor 17-DMAG causes massive 
necrosis in xenografted MLS tumors
An MLS tumor was serially transplanted in BALB/C 
NUDE mice and grew with the typical histological 
features of MLS (Figure 4A and Supplementary 
Figure 2A). Xenografts from two mice, each carrying 
two tumors, were treated for three days, one injection/
day with 17-DMAG. Three of four tumors showed 
hemorrhages with scattered extravasated erythrocytes 
and extensive coagulation type necrosis of tumor cells as 
well as of small vessels. The fourth and smallest tumor 
showed smaller affected areas and no hemorrhages. Four 
tumors analyzed after two weeks of treatment showed 
similar morphological changes. The extent of necrosis 
remained with a peripheral rim of viable tumor cells and 
without evidence of adipogenic maturation or stromal 
hyalinization (Figure 4B and Supplementary Figure 2B).
In a separate experiment, 4 animals, each carrying 
two tumors were given three injections of 17-DMAG with 
48 hours intervals. This was repeated for two weeks with 
a 72 hours interval after the third injection. This treatment 
caused no dramatic changes in tumor size during, or 
immediately after the treatment period, but most tumors 
decreased slowly in size or halted their growth during an 
83 day follow up period (Figure 4C). 
DISCUSSION
Our previous search for possible downstream 
target genes of FUS-DDIT3 identified RET as a candidate 
[8] and meta-analysis of microarray data in this study 
confirmed expression of RET as a characteristic of MLS 
(Supplementary Data Table 1). Expression of RET in MLS 
has independently been reported by others and higher 
expression level has been associated with poor survival 
[18, 26, 27]. Here, we show that PSPN, one GDNF-family 
member ligand of RET, is expressed in MLS and that the 
RET protein is phosphorylated at tyrosine 905 (Y905) as 
a sign of receptor activation [28–33]. PSPN binds to RET 
in complex with glycosyl-phosphatidyl inositiol (GPI)-
anchored co-receptors GFRα1–4 [13–15, 34, 35]. We did 
not detect any GFRα1–4 transcripts in the tumors or cell 
lines. However, GFRα1–4 independent ligand binding 
and RET signaling has been described [36], indicating 
a possible role for autocrine RET activation by PSPN in 
MLS. Expression of Artemin, another RET ligand and 
the RET coreceptor GFRα3 has been reported in MLS by 
Negri et al. [18], but we have, for unknown reasons, not 
detected transcripts/proteins from these genes in our cohort 
of MLS. Taken together, the expression of RET in MLS 
and the reported function of RET in cell survival/growth 
mechanisms, suggests that this RTK may be important 
in MLS pathogenesis. These results also provided a 
rationale for trying to block RET Y905 phosphorylation 
with the RET specific TK inhibitor Vandetanib. This drug 
failed, however, to block RET Y905 phosphorylation or 
cell growth indicating that RET phosphorylation was 
maintained by a Vandetanib resistant kinase, possibly 
another RTK species that could form complex with RET. 
Our screen for phosphorylated RTKs pointed out 
EGFR and ERBB3 as the most abundantly expressed 
in MLS. Using PLA and co­IP techniques, we showed, 
for the first time, that RET and ERBB3 form hetero­
complexes. ERBB3 forms hetero-complexes with several 
other members of the EGFR RTK family but cannot form 
homodimers [24]. Adding to the complicated scenario of 
interacting RTKs, a previous report also suggest that RET 
may interact with and be phosphorylated by the MET RTK 
in MLS [18]. MLS cells thus contain at least four distinct 
RTK species (RET, EGFR, MET and ERBB3) that can 
form various complexes around RET. This could result in 
deregulated RTK activation and increased growth/survival 
of the tumor cells.
The finding that RET may form dimers with EGFR 
[17], provided a rationale for trying to block RET Y905 
phosphorylation and growth/survival with the EGFR 
specific RTK inhibitor Gefitinib or combinations of 
Gefitinib and Vandetanib. No decrease in cell growth 
was observed at concentrations within the range of RTK 
specificity, indicating that the survival/growth supporting 
activity was maintained by a Gefitinib and Vandetanib 
resistant mechanism. The cytoplasmic tyrosine kinase 
SRC has been reported to phosphorylate RET at Y905 
and promote RET protein activity [37]. This SRC activity 
could possibly explain the Vandetanib resistance of RET 
in MLS is compatible with the reported growth inhibiting 
and cytotoxic effects of a specific SRC inhibitor in MLS 
cells [38]. 
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Our IHC analysis showed that RET and ERBB3 
was expressed as cytoplasmic/nuclear proteins and this 
was confirmed by PLA analysis (Figure 2D, 2E and 
Supplementary Film Clips 1–3) and western blot analysis 
of cytoplasmic and nuclear cell fractions (Figure 3B) . 
Nuclear, smaller variants of ERBB3 have been reported 
to bind the promoter and activate transcription of the 
cyclin D1 gene (CCND1) [39]. We could not detect 
shorter ERBB3 variants in MLS but found the full-length 
protein in nuclear MLS extracts (Figure 3A). A role for 
Figure 3: In vitro effects of 17-DMAG treatment. (A) Cell survival after 17-DMAG treatment. Cell density measured after 72 hours 
treatment of MLS cell lines (402–91, 1765–92 and 2645–94) and normal fibroblasts (F470) with various 17­DMAG concentrations. Values 
normalized against untreated control cells. Standard error of mean, indicated as error bars, was calculated from four replicates in different 
wells of the plate. (B) Western blot analysis of total and phosphorylated RTKs extracted from cytoplasmic and nuclear fractions of MLS cell 
lines after 24 hours of treatment with 30 nM 17-DMAG as indicated. Nuclear and cytoplasmic fractions indicated by N and C respectively. 
Loading and fraction controls: GAPDH (cytoplasmic) and Lamin A (nuclear).
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nuclear ERBB3 in CCND1 regulation is compatible with 
the reported strong expression of CCND1 in MLS [19]. 
Nuclear expression and specific nuclear down­stream 
effects have been reported for many different RTK species 
including EGFR, ERBB3 and RET [40–43]. Nuclear RET 
expression was reported to cause phosphorylation of the 
apoptosis promoting transcription factor ATF4 and thus 
inhibit apoptosis and promote survival [43]. The nuclear 
expression of ERBB3 together with RET in MLS may thus 
be central for MLS pathogenesis. 
We have previously reported a cytoplasmic/nuclear 
expression of the FLT1 receptor tyrosine kinase and its 
ligand PLGF in MLS [44]. Taken together, at least three 
RTK species (RET, ERBB3, FLT1)with two of their 
ligands (PSPN, PGF) show a nuclear localization in 
these cells. This unusual expression pattern stands out as 
Figure 4: Histology of MLS xenografts from NUDE mice. (A) Control tissue showing typical MLS features with prominent myxoid 
matrix, lipoblasts and capillary vessels. Overview panel at 4 times, and close up border and central zone panels at 12 times magnification. 
(B) Tumor tissue one week after 3 days of 17-DMAG treatment, 25 mg/Kg. Note extensive cell loss, rupture of capillary vessels and bleeding. 
See also microphotographs at higher resolution in Supplementary Figure 2. (C) Follow up on tumor volume in control and 17-DMAG treated 
animals. Time point for first injection at 100 days after first tumor measurement is indicated. Tumor growth was followed for 83 days after 
first injection. The mice were given three injections with 48 hours intervals, repeated for two weeks with a 72 hours break after injection 3. 
Data from 8 treated and 8 control tumors is shown as relative mean volumes using data from first measurements as base value. Standard 
error and significant differences according to t-test are shown as bars and stars.
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typical for MLS compared to normal mesenchymal cells. 
Cross activation between these and perhaps additional 
tyrosine kinases may thus be an essential function for self-
sustaining growth and survival of MLS cells and could 
also cause the observed resistance to RTK inhibitors [45].
RTK activation and complex formation has been 
reported to depend on HSP90 activity [45, 46]. Our data 
shows that inhibition of HSP90 functions lead to loss of 
RET and ERBB3 phosphorylation. It also caused growth 
cessation and death of MLS cells in vitro and extensive 
necrosis of xenografted MLS tumors. The cytostatic in 
vitro effects of HSP90 inhibition in MLS cell lines has 
recently been reported for an unrelated HSP90 inhibitor 
[47], confirming the MLS sensitivity to this class of drugs.
Several mechanisms for HSP90 inhibitor induced 
cell death have been described including inhibition/
degradation of RTKs [45, 46, 48–51]. HSP90 has a large 
number of client proteins and inhibition can be expected 
to affect many cellular functions leading to cell death. 
However, normal cells, including the human fibroblasts 
used as in vitro controls here, were highly resistant to 
HSP90 inhibitors. An outstanding difference between 
normal fibroblasts and MLS cells, is the co­expression 
and nuclear expression of RET and ERBB3. This 
difference may play an important role in the vulnerability 
of MLS cells exposed by HSP90 inhibition. The fact 
that 17-DMAG caused decreased ERBB3 and RET 
phosphorylation with maintained total levels of these 
proteins prior to cell death supports this conclusion.
Our in vitro results lead us to try HSP90 inhibitor 
treatment in an MLS xenograft model. This tumor has 
been serially transplanted from the patient and was not 
passaged in culture. It closely recapitulates the typical 
histology and slow growth pattern of MLS tumors. 
HSP90 inhibitor treatment caused massive cell death and 
bleeding/rupture of tumor capillaries. Macroscopically, 
the tumor tissues showed a slow decline or in some cases 
stable size. Histological examination revealed narrow 
marginal regions of surviving tumor cells several months 
after finished treatment. These surviving tumor cells may 
be senescent since MLS tumors contain major populations 
of resting and senescent cells [52]. Senescent cells are still 
capable of maintaining the extensive extracellular matrix 
[53], and could therefore prevent fast shrinkage of 17-
DMAG treated tumor tissues. The small and slow size 
reduction of MLS tumors stands in contrast to the dramatic 
histological findings and has to be taken into consideration 
when clinical trials with MLS patients are to be evaluated. 
We conclude that MLS cells express a mix of 
interacting RTKs and their ligands that could cross interact 
and cause their resistance to RTK inhibitors. Inhibition 
of HSP90 activity could overcome this resistance as 
shown by reduced RTK phosphorylation/proliferation 
and massive death of the tumor cells in vitro and in vivo. 
HSP90 inhibitors are therefore attractive drug candidates 
for treatment of MLS.
MATERIALS AND METHODS
Tissue samples
The tumor material is summarized in Table 1. 
Formaldehyde fixed tissues were embedded in paraffin and 
fresh tissues were frozen and stored at –140oC. 
Table 1: Cell lines and tissue samples
SAMPLE NUMBER TUMOR TYPE SAMPLE FUS-DDIT3**
402–91 MLS Cell line +
1955–91 MLS Cell line +
2645–94 MLS Cell line +
1765–92 MLS Cell line +
Case1 MLS Tissue +
Case2 MLS Tissue +
Case3 MLS Tissue +
Case4 MLS Tissue +
Case5 MLS Tissue +
Case6 MLS Tissue +
Case7 MLS Tissue +
Case8 MLS Tissue +
Xenograft MLS Tissue +
**Results from RT-PCR experiment
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Cell culture and cell lines
SV40 large T transformed myxoid liposarcoma cell 
lines 1955–91, 1765–92, 402–91 and 2645–94 [54–56] , 
normal human fibroblasts F470, passages 4–8, MCF­7 
(human breast cancer line), HT1080(human fibrosarcoma 
cell line [57]), were cultured in RPMI1640 with 8% fetal 
calf serum. All media and supplements were obtained 
from Life Technologies. Transfections were made 
with FUGENE 6 reagent (Promega) according to the 
manufacturers protocoll. ERBB3 cDNA clone (Addgene 
23874) was inserted into a pEGFP-N1 vector (Clontech) 
and one control sequenced clone was used for transfection.
Proliferation and cytotoxicity assay
Cells were seeded to 96-well microtiter plates. Drugs 
were added after 24 hours at different concentrations. 
Each test was set up in three or more replicates. The 
medium was removed and plates were washed 72 hours 
after treatment and stored in –80°C until analysis. The 
cells were lysed and DNA was stained using a Cell 
Proliferation Assay Kit (Molecular probes, C–7026) 
according to the manufacturers manual, and analyzed in 
a SpectraMaxGeminiXS (Göteborgs Termometerfabrik 
Gothenburg Sweden) or in a VICTOR3 multilabel plate 
reader (PerkinElmer).
Nucleic acid extractions
DNA was extracted from frozen tumor tissues as 
described [2]. RNA was extracted from tumor tissues using 
a Fastprep kit (Bio101) according to the manufacturer’s 
recommenda tions. RNA was extracted from cultured cells 
as described [58].
RT-PCR analysis 
RT-PCR analysis was performed with the following 
RET primers: RET 225 5′­GGCTGCGTCTGCTGTGC 
TG and RET466 5′­AAGGTGAGGAGGCCGGTGTC, 
covering sequences encoding extracellular parts, RET 
2185 5′­GCCCACAGCCACCCAT and RET 2469 5′­GGA 
GGCGTTCTCTTTCAGCATC, covering transmembrane 
encoding parts, RET2738 5′­TGGGCGACCTCATCTC 
ATTTG and RET3271 5′­AGGCCGTCG TC ATAAATC 
AGGGAG, covering the tyrosine kinase encoding 
sequences of RET mRNA. For the analysis of ligand 
transcripts, the GDNF specific primers GDNF fwd 
5′­ATGT CGTGGCTGTCTGCCTGG and GDNF rev 
5′­CATC GCA AGA GCCGCTGCAG, the PSPN specific 
primers PSPN90fwd 5′­CGTGGCCGATGG A G AGT T 
C TC and PSPN rev 5′­AAGGCCAC G T C GG TG TA GCG, 
the NRTN specific primers NTNfwd 5′­AGA GG GCC 
TGCTTCTCAGCC and NTNrev 5′­TAGCGGAACAGC 
ACCGTCTCG, and the ARTN specific primers 
ARTNfwd 5′­TGCTGAGCAGCGTCGCA GA G G and 
ARTNrev 5′­A GG A GC CG C T GC AG A A G C GG, were 
used. To avoid amplification of contaminating genomic 
DNA, all primer pairs were designed to amplify cDNA 
fragments that spanned over one or several exon 
borders. Unigene representative sequences were used as 
template for primer design. PCR was run for 35 cycles 
using a GCRICH PCR system (Roche Diagnostics) and 
AmpliTaq GOLD Polymerase (Perkin­Elmer) according 
to the manufacturer’s re commen dations. PCR detection of 
FUSDDIT3 fusion transcripts was performed as previously 
described [4, 56].
Mutation analysis
Exons 10 and 11 of the RET gene were amplified from 
genomic tumor DNA by PCR using the following primers: 
CRT19S 5′­GCAGCATTGTTGGGGGACA (exon 10, 
forward), CRT 2A 5′­GACAGCAGCACCGAGAC GAT 
(exon 10, reverse), MENF 5′­CATGAGGCCGA 
GCATACTCAGCC (exon 11, for ward), MENR 5′­CA 
GAC AG CA GCGCCG AG ACG A TG (exon 11, reverse). 
Amplification was accomplished by 35 cycles using the 
following parameters: de naturation 94°C for 45 seconds, 
annealing 56°C for 90 seconds, extension 72°C for 90 
seconds. PCR products were purified on Microspin S300 
HR columns (Pharmacia Biotech, Uppsala, Sweden). An 
aliquot (5–10 ml) of the purified PCR product served 
as template in a Big Dye Terminator Cycle Sequencing 
Ready Reaction procedure (PE-biosystems no 4303152) 
and the product was analyzed in an ABI PRISM 377 DNA 
sequencer (Perkin Elmer Biosystems, Foster City, CA). 
Forward primers were used for the sequencing procedure 
and each sample was analysed in at least three separate 
reactions. Sequences were analysed using the Sequence 
Navigator software.
Immunohistochemistry (IHC) 
Sections were cut from blocks with formaldehyde 
fixed paraffin embedded tumor tissues, deparaffinized 
and stained with primary antibodies specific for RET and 
PSPN, (Santa Cruz Biotechnology, product numbers SC-
167 and SC-8684, respectively). The RET antibody was 
used at 1:100 dilutions whereas the PSPN antibody was 
applied at a 1:20 dilution. Exclusion or replacement of 
primary antibodies from the IHC protocol abolished all 
staining of the tissue sections.
Proximity ligation assay
The proximity ligation assays was performed with 
a DuoLink II kit(Olink Bioscience) according to the 
manufacturers protocols and as described [58]. DuoLink 
rabbit and goat specific probes were used in combination 
with ERBB3 specific rabbit antibody (G­4) (1:300) and 
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RET specific goat antibody (C­19) (1:200), both from 
Santa Cruz Biotechnology. Assays with unmatched first 
antibodies and DuoLink probes and with single DuoLink 
probes were used as negative controls and gave no 
background signals.
Microphotographs were captured on a Zeiss LSM 
700 confocal microscope and deconvolution, image 
analysis, quantification of PLA spots and animation 
clips were made with the Volocity soft-ware package, 
(PerkinElmer Inc). The deconvolution was performed 
using iterative restoration with a calculated point spread 
function. 
Western blots analysis 
Whole cell extracts were prepared as described 
[58] and separated on a 4–12% SDS-PAGE gel (Life 
Technologies as previously described [59]. The proteins 
were blotted on Immobilon™-P PVDF membranes 
(Millipore Corporation) or Invitrolon PVDF membranes 
(Life Technologies) and detected using the following 
antibodies: RET (C-19), goat polyclonal (Santa Cruz 
Biotechnology); phospho-RET Tyr-905, rabbit polyclonal 
(Cell Signaling Technology); Persephin (N18 and C17), 
goat antisera (Santa Cruz Biotechnology); EGFR (E30), 
mouse monoclonal (DAKO); phospho-EGFR Tyr-1068 
(1H12), mouse monoclonal (Cell Signaling Technology); 
ERBB3 (G-4), mouse monoclonal (Santa Cruz 
Biotechnology); phospho-ERBB3 Tyr-1289 (21D3), rabbit 
monoclonal (Cell Signaling Technology); GFP (JL-8) 
mouse monoclonal (Clontech); GAPDH (mAbcam 
9484), mouse monoclonal (Abcam); Lamin A (133A2), 
mouse monoclonal (Abcam). RP-conjugated secondary 
antibodies were used: Stabilized Goat Anti-Mouse IgG 
(H + L), Peroxidase Conjugated (Thermo Scientific 
Pierce); Stabilized Goat Anti-Rabbit IgG (H + L), 
Peroxidase Conjugated (Thermo Scientific Pierce); bovine 
anti-goat IgG-HRP (Santa Cruz Biotechnology). 
All antibodies were evaluated by tests on positive 
and negative control western blot samples and normal 
human tissue sections with published and established 
expression patterns of EGFR, ERBB3 and RET in specific 
cell types as described [19]. Extracts from human cultured 
fibroblasts were used as control for RET, Persephin and 
ERBB3 proteins. Breast cancer cell line MCF-7 was used 
as positive control of ERBB3. 
Preparation of cytoplasmic and nuclear extracts 
was made from trypsin detached cell suspensions that 
were washed twice in PBS and suspended in 100 μl of 
ice-cold lysis buffer containing 50 mM NaCl, 4 mM 
MgCl2, 10 mM TRIS PH 6. 8, 0, 5% TritonX. The cells 
were disrupted by repeated pipetting for 5 minutes on ice. 
Nuclei were pelleted by centrifugation at 14000 rpm for 
15 minutes. Cytoplasmic (supernatant) and nuclear (pellet) 
fractions were collected and diluted 1: 4 with 4 × NuPAGE 
LDS sample buffer (Life technologies) for Western blot 
analysis. Immunoprecipitation of GFP tagged ERBB3 was 
made 24 hours after transfection. Cells were harvested and 
suspended in lysis buffer (25 mM Tis pH 7.5, 150 mM 
KCl, 1,5 mM MgCl, 1 mM DTT, and 0,5% NP 40. After 
30 minutes on ice followed by a 10 minutes centrifugation 
at 16000 × G, the supernatant was diluted to 0,2% NP40. 
Immunoprecipitation was performed with GFP-TRAP 
beads (Chromotek) according to the manufacturers 
protocol.
Animals and drug treatment
Five to six weeks old BALB/C NUDE mice 
(Janvier Labs) were transplanted with approximately 
2 × 2 mm large tumor pieces. Mice with tumor sizes 
from 8 × 8 mm were used for drug treatment tests. Tumor 
sizes were measured in mm with a caliper from 14 days 
after transplantation and volume calculated according 
to Feldman et al. [60]. 17-DMAG (Selleckchem) was 
dissolved in 150 mM NaCl to a final concentration of 
1 mg/ml and stored frozen. The drug was administered 
by peritoneal injections (25 mg/Kg body weight). Drug 
treatment was started 114 days after transplantation with 
three injections at 48 hours intervals repeated for two 
weeks with a 72 hours break after injection 3. Tumor sizes 
were followed up for 83 days after first injection. The 
mice were sacrificed by cervical dislocation and tumors 
were immediately collected and transferred to ice-cold 4% 
formaldehyde in PBS. 
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